Hospital
Chi ST Vincent Hospital Hot Springs
Chi ST Vincent Hospital Hot Springs was paid $16.38M by Medicaid between Jan 2018 and Dec 2024, across 359 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 6.5% of everything it billed.
33Billing provider infoCHI ST VINCENT HOSPITAL HOT SPRINGS
HOT SPRINGS, AR 71913
HOT SPRINGS, AR 71913
33aNPI1689628232assigned 05/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.38M
24GClaims829,433
24DCodes billed359
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arkansas
Rank by total paid#6 of 49
Median peer was paid$2.62M
This provider vs. median6.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 134,038 | $2.28M | |
| 2019 | 135,484 | $2.82M | |
| 2020 | 115,401 | $2.44M | |
| 2021 | 108,829 | $2.18M | |
| 2022 | 123,668 | $2.40M | |
| 2023 | 118,735 | $2.48M | |
| 2024incomplete | 93,278 | $1.79M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 6.5% | 15,143 | 12,878 | $1.07M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.5% | 6,684 | 6,092 | $896K |
| 59025 | Fetal non-stress test | 5.0% | 6,950 | 3,260 | $826K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.4% | 7,440 | 6,754 | $715K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.8% | 5,861 | 4,963 | $629K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.9% | 35,468 | 27,503 | $483K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.7% | 4,475 | 4,036 | $448K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 2.7% | 1,429 | 1,254 | $447K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.7% | 55,843 | 44,719 | $446K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.7% | 4,123 | 2,115 | $440K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 2.4% | 1,742 | 1,516 | $392K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.4% | 15,212 | 4,633 | $392K |
347 more codes
| 72125 | Computed tomography, cervical spine; without contrast material | 2.1% | 3,007 | $342K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.1% | 4,132 | $337K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | 2.0% | 38,531 | $321K |
| 80053 | Comprehensive metabolic panel | 1.9% | 19,486 | $308K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.9% | 1,960 | $304K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.7% | 1,774 | $271K |
| 36415 | Collection of venous blood by venipuncture | 1.6% | 25,245 | $261K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.6% | 2,272 | $256K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.4% | 1,311 | $228K |
| 99283 | Emergency room visit (moderate) | 1.4% | 5,779 | $222K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 1.3% | 1,041 | $217K |
| 99284 | Emergency room visit (serious) | 1.2% | 8,327 | $198K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.2% | 4,504 | $195K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.2% | 4,505 | $195K |
| 80081 | 1.1% | 1,871 | $172K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 2,529 | $166K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.0% | 18,084 | $165K |
| 72141 | <1% | 639 | $137K | |
| 71045 | Radiologic examination, chest; single view | <1% | 15,739 | $135K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 16,115 | $133K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 476 | $130K |
| 80047 | <1% | 2,059 | $123K | |
| 84484 | <1% | 11,445 | $119K | |
| 99285 | Emergency room visit (most serious) | <1% | 3,696 | $116K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,021 | $107K |
| 86901 | <1% | 4,412 | $106K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,414 | $90K |
| 81025 | <1% | 10,456 | $89K | |
| 87653 | <1% | 1,926 | $89K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 189 | $85K |
| 97161 | <1% | 2,027 | $82K | |
| 87088 | <1% | 8,625 | $77K | |
| 83880 | <1% | 2,951 | $75K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 377 | $68K |
| 83690 | <1% | 9,338 | $67K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,034 | $60K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 19,432 | $57K |
| 71250 | <1% | 782 | $57K | |
| 80074 | <1% | 1,292 | $56K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 2,000 | $56K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,452 | $55K |
| 73221 | <1% | 208 | $53K | |
| 90715 | <1% | 2,470 | $50K | |
| 82077 | <1% | 3,161 | $50K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,777 | $49K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 147 | $49K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,065 | $46K |
| 82947 | <1% | 6,843 | $45K | |
| 80061 | Lipid panel | <1% | 3,413 | $45K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,456 | $45K |
| 87077 | <1% | 5,599 | $45K | |
| 95811 | <1% | 310 | $41K | |
| 82105 | <1% | 2,037 | $41K | |
| 82803 | <1% | 2,264 | $41K | |
| 94760 | <1% | 2,474 | $40K | |
| 84702 | <1% | 3,864 | $39K | |
| 82677 | <1% | 1,268 | $39K | |
| 80320 | <1% | 2,572 | $37K | |
| 70486 | <1% | 339 | $37K | |
| 86003 | <1% | 382 | $37K | |
| 74420 | <1% | 685 | $37K | |
| 97001 | <1% | 1,275 | $36K | |
| 81001 | <1% | 11,320 | $36K | |
| 81003 | <1% | 15,289 | $35K | |
| 93017 | <1% | 2,093 | $35K | |
| 72131 | <1% | 322 | $35K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,805 | $35K |
| 93971 | <1% | 1,030 | $34K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,002 | $34K |
| 87081 | <1% | 4,189 | $34K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,387 | $33K |
| 80076 | <1% | 3,846 | $32K | |
| 80143 | <1% | 1,606 | $32K | |
| 80179 | <1% | 1,600 | $30K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,607 | $30K |
| 74018 | <1% | 1,787 | $30K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 689 | $29K |
| 86900 | <1% | 4,286 | $29K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 264 | $29K |
| 87186 | <1% | 5,594 | $29K | |
| 86850 | <1% | 4,000 | $28K | |
| 83605 | <1% | 2,704 | $27K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,962 | $27K |
| 93458 | <1% | 191 | $27K | |
| 72100 | <1% | 1,090 | $27K | |
| 97597 | <1% | 2,338 | $27K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 570 | $25K |
| 87070 | <1% | 2,553 | $25K | |
| 86336 | <1% | 1,268 | $25K | |
| 94726 | <1% | 1,193 | $25K | |
| 97165 | <1% | 805 | $24K | |
| 85610 | <1% | 7,143 | $24K | |
| 73030 | <1% | 990 | $23K | |
| 94761 | <1% | 1,687 | $21K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,899 | $21K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,942 | $21K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,560 | $21K |
| 72170 | <1% | 1,186 | $21K | |
| 80050 | General health panel | <1% | 742 | $20K |
| 76642 | <1% | 783 | $20K | |
| 84703 | <1% | 1,995 | $20K | |
| 73630 | <1% | 732 | $20K | |
| 82962 | <1% | 4,885 | $19K | |
| 86592 | <1% | 3,859 | $19K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,421 | $19K |
| 87040 | <1% | 1,531 | $19K | |
| 73560 | <1% | 816 | $18K | |
| 80329 | <1% | 1,199 | $18K | |
| 83735 | <1% | 3,541 | $18K | |
| 12001 | <1% | 80 | $17K | |
| 73130 | <1% | 681 | $17K | |
| 94729 | <1% | 1,187 | $17K | |
| 77066 | Tomosynthesis, mammo | <1% | 264 | $17K |
| C1769 | Guide wire | <1% | 320 | $16K |
| 77336 | <1% | 328 | $16K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,027 | $16K |
| 87147 | <1% | 1,612 | $16K | |
| 73610 | <1% | 801 | $16K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 760 | $16K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 485 | $15K |
| 80164 | <1% | 1,140 | $14K | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 723 | $14K |
| 85730 | <1% | 2,809 | $14K | |
| 86803 | <1% | 766 | $13K | |
| 85027 | <1% | 3,252 | $13K | |
| 85379 | <1% | 1,342 | $12K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 57 | $12K |
| 84439 | <1% | 1,558 | $11K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,182 | $11K |
| 76801 | <1% | 322 | $11K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,809 | $11K |
| 87807 | <1% | 877 | $11K | |
| 87210 | <1% | 1,946 | $11K | |
| 77334 | <1% | 60 | $10K | |
| 77065 | Tomosynthesis, mammo | <1% | 224 | $10K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 222 | $9K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 178 | $9K |
| 87641 | <1% | 447 | $8K | |
| 36600 | <1% | 396 | $8K | |
| 73110 | <1% | 325 | $8K | |
| 36416 | <1% | 2,300 | $8K | |
| 86140 | <1% | 1,921 | $8K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,160 | $7K |
| 70498 | <1% | 79 | $7K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,223 | $7K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 452 | $7K |
| 71010 | <1% | 922 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,987 | $6K |
| 86038 | <1% | 820 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,693 | $6K |
| 84145 | <1% | 385 | $6K | |
| 77412 | <1% | 145 | $6K | |
| 71271 | <1% | 57 | $6K | |
| 82565 | <1% | 461 | $6K | |
| 97602 | <1% | 249 | $6K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 2,286 | $6K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 16,662 | $6K |
| 87205 | <1% | 1,559 | $6K | |
| 90686 | <1% | 384 | $6K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 165 | $5K |
| 72040 | <1% | 313 | $5K | |
| 36430 | <1% | 75 | $5K | |
| 12011 | <1% | 25 | $5K | |
| 86762 | <1% | 272 | $5K | |
| 82785 | <1% | 297 | $5K | |
| 82550 | <1% | 756 | $5K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,685 | $5K |
| 88300 | <1% | 286 | $4K | |
| 97003 | <1% | 162 | $4K | |
| 83721 | <1% | 663 | $4K | |
| 88304 | <1% | 201 | $4K | |
| 76770 | <1% | 153 | $4K | |
| 94010 | <1% | 279 | $4K | |
| 86920 | <1% | 67 | $4K | |
| 87400 | <1% | 311 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,636 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,134 | $4K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 38 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,416 | $3K |
| 93976 | <1% | 59 | $3K | |
| 93798 | <1% | 295 | $3K | |
| 94060 | <1% | 192 | $3K | |
| 99152 | <1% | 232 | $3K | |
| 83525 | <1% | 212 | $3K | |
| 93880 | <1% | 113 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,241 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 8,725 | $3K |
| 84481 | <1% | 260 | $3K | |
| 71020 | <1% | 197 | $3K | |
| 99406 | <1% | 655 | $3K | |
| 87075 | <1% | 202 | $3K | |
| 70496 | <1% | 33 | $3K | |
| 74178 | <1% | 42 | $3K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 138 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,071 | $2K |
| 82731 | <1% | 28 | $2K | |
| 84156 | <1% | 630 | $2K | |
| 47562 | <1% | 15 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,785 | $2K |
| 87428 | <1% | 48 | $2K | |
| 84132 | <1% | 294 | $2K | |
| 74000 | <1% | 118 | $2K | |
| 77300 | <1% | 16 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,881 | $2K |
| 73070 | <1% | 91 | $2K | |
| 64721 | <1% | 14 | $2K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,496 | $2K |
| 86696 | <1% | 66 | $1K | |
| 70491 | <1% | 13 | $1K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 381 | $1K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,860 | $1K |
| 86376 | <1% | 162 | $1K | |
| 82553 | <1% | 146 | $1K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 115 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 880 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,511 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,822 | $1K |
| 87045 | <1% | 130 | $1K | |
| 73502 | <1% | 76 | $1K | |
| 76536 | <1% | 45 | $1K | |
| 83550 | <1% | 182 | $1K | |
| 80178 | <1% | 223 | $1K | |
| 87046 | <1% | 130 | $1K | |
| 86431 | <1% | 396 | $1K | |
| G0378 | Hospital observation service, per hour | <1% | 1,111 | $1K |
| 87899 | <1% | 137 | $1K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 616 | $1K |
| 86665 | <1% | 32 | $1K | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 439 | $991.90 |
| 51702 | <1% | 25 | $968.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 44 | $935.63 |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 29 | $932.00 |
| 83540 | <1% | 184 | $928.25 | |
| 84681 | <1% | 64 | $919.99 | |
| A9270 | Non-covered item or service | <1% | 6,486 | $877.30 |
| 80055 | <1% | 26 | $876.48 | |
| 82330 | <1% | 66 | $859.33 | |
| 74022 | <1% | 44 | $822.00 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 7,983 | $814.43 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,181 | $811.85 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,079 | $807.49 |
| G0008 | Administration of influenza virus vaccine | <1% | 118 | $762.29 |
| 77080 | <1% | 13 | $731.58 | |
| 85651 | <1% | 263 | $694.87 | |
| 83001 | <1% | 48 | $688.62 | |
| 86695 | <1% | 66 | $684.82 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 27 | $681.68 |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 64 | $663.84 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,929 | $660.96 |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 14 | $656.00 |
| 82248 | <1% | 100 | $641.78 | |
| 82607 | <1% | 64 | $626.78 | |
| 75635 | <1% | 14 | $601.97 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 12 | $598.69 |
| 86757 | <1% | 19 | $582.66 | |
| 73562 | <1% | 34 | $571.15 | |
| 76830 | Ultrasound, transvaginal | <1% | 12 | $562.36 |
| 82010 | <1% | 81 | $547.09 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 934 | $536.65 |
| 81050 | <1% | 159 | $527.60 | |
| 81002 | <1% | 155 | $492.42 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 833 | $490.72 |
| 97016 | <1% | 365 | $488.97 | |
| 86664 | <1% | 30 | $458.64 | |
| 86039 | <1% | 65 | $458.20 | |
| 84153 | <1% | 32 | $450.36 | |
| 84146 | <1% | 27 | $438.52 | |
| 96367 | <1% | 16 | $430.88 | |
| 76870 | <1% | 16 | $420.11 | |
| 86663 | <1% | 30 | $393.33 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,302 | $373.59 |
| 72050 | <1% | 16 | $362.33 | |
| 72110 | <1% | 28 | $362.30 | |
| 73590 | <1% | 17 | $350.00 | |
| 87340 | <1% | 28 | $339.25 | |
| 82272 | <1% | 78 | $301.36 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 166 | $270.11 |
| 94618 | <1% | 43 | $259.88 | |
| 86800 | <1% | 29 | $255.94 | |
| 83970 | <1% | 16 | $252.28 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 301 | $243.04 |
| 82247 | <1% | 33 | $236.61 | |
| 73090 | <1% | 13 | $233.13 | |
| 70360 | <1% | 26 | $232.70 | |
| 86694 | <1% | 16 | $231.60 | |
| 77417 | <1% | 24 | $215.02 | |
| 97014 | <1% | 730 | $213.39 | |
| 87493 | <1% | 14 | $207.80 | |
| 82570 | <1% | 53 | $202.25 | |
| 90656 | <1% | 21 | $200.34 | |
| 82150 | <1% | 31 | $191.38 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 145 | $182.86 |
| 82533 | <1% | 24 | $180.24 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 179 | $177.35 |
| 84100 | <1% | 96 | $175.95 | |
| 86141 | <1% | 13 | $161.41 | |
| 82728 | <1% | 14 | $156.43 | |
| 87430 | <1% | 13 | $151.94 | |
| 84295 | <1% | 30 | $149.82 | |
| 95816 | <1% | 14 | $141.00 | |
| 85014 | <1% | 55 | $128.75 | |
| 83520 | <1% | 13 | $112.73 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 349 | $111.38 |
| 83986 | <1% | 30 | $107.52 | |
| 87449 | <1% | 17 | $90.09 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 28 | $70.86 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,008 | $68.06 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 120 | $65.82 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 105 | $65.81 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 199 | $61.81 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 42 | $45.87 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 30 | $45.45 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 85 | $44.34 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 60 | $41.52 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 59 | $35.37 |
| 97116 | <1% | 951 | $33.39 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 292 | $27.95 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 69 | $27.86 |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 58 | $26.00 |
| 96376 | <1% | 2,560 | $25.79 | |
| 84460 | <1% | 13 | $22.68 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 217 | $20.28 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 80 | $16.29 |
| 97760 | <1% | 14 | $11.07 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 15 | $10.59 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 148 | $10.36 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 113 | $5.12 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 14 | $2.52 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 39 | $2.00 |
| 97010 | <1% | 162 | $1.95 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 236 | $0.32 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 249 | $0.29 |
| 97802 | 0% | 27 | $0.00 | |
| 96373 | 0% | 12 | $0.00 | |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 47 | $0.00 |
| 94762 | 0% | 345 | $0.00 | |
| 82043 | 0% | 14 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 29 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 46 | $0.00 |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 0% | 14 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 30 | $0.00 |
| 93356 | 0% | 64 | $0.00 | |
| 36592 | 0% | 13 | $0.00 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | 0% | 39 | $0.00 |
| 94799 | 0% | 15 | $0.00 | |
| J1598 | Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg | 0% | 70 | $0.00 |
| S0164 | Injection, pantoprazole sodium, 40 mg | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSZOSTEK, JOSHUA (VP OPERATIONAL FINANCE)
| Provider | Location | Paid |
|---|---|---|
| ST Vincent Infirmary Medical Center | Little Rock, AR | $8.31M |
| ST. Vincent Infirmary Medical Center | Sherwood, AR | $2.98M |
| Chi ST Vincent Hospital Hot Springs | Hot Springs, AR | $236K |
| ST. Vincent Infirmary Medical Center | Little Rock, AR | $121K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.